N
Nuvation Bio Inc. (NUVB)
NYQ – Real Time Price. Currency in USD
4.84
+0.08 (1.68%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NYQ – Real Time Price. Currency in USD
4.84
+0.08 (1.68%)
At close: May 12, 2026, 4:00 PM EDT
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
| Name | Position |
|---|---|
| Dr. David Liu M.D., Ph.D. | Chief Medical Officer |
| Dr. David C. Hanley Ph.D. | Chief Technical Operations Officer |
| Dr. David T. Hung M.D. | Founder, President, CEO & Chairman |
| Dr. Gary Hattersley Ph.D. | Chief Scientific Officer |
| Dr. Stephen Dang Ph.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Moses Makunje CPA | VP of Finance and Principal Accounting & Financial Officer |
| Mr. Philippe Pierre Sauvage | CFO & Principal Financial Officer |
| Ms. Colleen Sjogren | Chief Commercial Officer |
| Ms. Kerry A. Wentworth | Chief Regulatory Officer |
| Ms. Stacy Markel | Chief People Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-04 | 8-K | d132166d8k.htm |
| 2026-04-21 | DEFA14A | ef20071024_defa14a.htm |
| 2026-04-10 | DEF 14A | nuvb-20260521.htm |
| 2026-04-10 | ARS | ny20065562x2_ars.pdf |
| 2026-03-03 | S-8 | d112224ds8.htm |
| 2026-03-02 | 8-K | d15383d8k.htm |
| 2026-01-12 | 8-K | d947742d8k.htm |
| 2025-11-26 | 8-K | d82457d8k.htm |
| 2025-11-17 | 8-K | d845081d8k.htm |
| 2025-11-03 | 10-Q | nuvb-20250930.htm |